BYDUREON is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2D) who are receiving a stable dose of oral antihyperglycemic therapy (OADs) and who are not achieving adequate glycemic control with their current therapy. It is available as BYDUREON pen injectable suspension (package insert) and as BYDUREON SoloSTAR device (device insert).

**CONVENIENT ONCE-DAILY DOSING**
- Once-daily dosing provides flexibility for both patient and provider.
- Ideal for patients with busy lifestyles.

**Use in Specific Populations**
- **Patients on Dialysis:**
  - Use of BYDUREON in patients on dialysis has not been studied.
  - Use with caution and monitor closely.

**Important Safety Information for BYDUREON (cont'd)**

**Adverse Reactions**
- **Most common adverse reactions (≥5%):**
  - Constipation
  - Hypoglycemia
  - Headache

**Warnings and Precautions**
- **Prior serious hypersensitivity reaction to FARXIGA:**
  - Discontinue FARXIGA if you have a serious hypersensitivity reaction to FARXIGA.

**Contraindications**
- **FARXIGA is not indicated for the treatment of hypertension.**

**Dosage and Administration**
- The recommended starting dose of BYDUREON is 0.6 mg once daily, which can be titrated up to 1.2 mg once daily.

**Adherence Programs**
- **FARXIGA Compliance Card:**
  - Helps patients track their medication adherence.
  - Encourages timely refills and reduces medication errors.

**FARXIGA with Abbott Diabetes Care**
- Abbott Diabetes Care provides a comprehensive suite of services to help patients manage their diabetes.

**Financial Assistance**
- **FOR ADULTS WITH TYPE 2 DIABETES**
  - **¶P<0.0001 vs glipizide + metformin.**
  - **‡Secondary end point: Mean weight reduction at 24 weeks.**

**SECONDARY END POINT:
- Mean change from baseline in HbA1c over 24 weeks**

<table>
<thead>
<tr>
<th>Group</th>
<th>HbA1c Change (mmol/mol)</th>
<th>Weight Change (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FARXIGA 5 mg + metformin n=370</td>
<td>-1.0</td>
<td>-7.3</td>
</tr>
<tr>
<td>Glipizide + metformin  n=370</td>
<td>-0.9</td>
<td>-2.3</td>
</tr>
<tr>
<td>Placebo                n=194</td>
<td>-1.8</td>
<td>-2.9</td>
</tr>
</tbody>
</table>

**kos to improve glycemic control in patients with T2D, the recommended starting dose of FARXIGA is 5 mg orally once daily, which can be adjusted up to 10 mg once daily based on blood glucose control.**

**Precautions**
- **Before initiating FARXIGA, consider risk factors for ketoacidosis.**
- **Patients on FARXIGA may require monitoring and management of electrolytes and fluid balance.**

**FARXIGA increases the risk of genital mycotic infections, particularly in patients with established CV disease or multiple CV risk factors.**

**Step edits may apply.**

**References**